Tumour	0	6	B-Pathological_formation
angiogenesis	7	19	O
:	19	20	O
its	21	24	O
mechanism	25	34	O
and	35	38	O
therapeutic	39	50	O
implications	51	63	O
in	64	66	O
malignant	67	76	O
gliomas	77	84	B-Pathological_formation
.	84	85	O

Angiogenesis	87	99	O
is	100	102	O
a	103	104	O
key	105	108	O
event	109	114	O
in	115	117	O
the	118	121	O
progression	122	133	O
of	134	136	O
malignant	137	146	O
gliomas	147	154	B-Pathological_formation
.	154	155	O

The	156	159	O
presence	160	168	O
of	169	171	O
microvascular	172	185	B-Tissue
proliferation	186	199	O
leads	200	205	O
to	206	208	O
the	209	212	O
histological	213	225	O
diagnosis	226	235	O
of	236	238	O
glioblastoma	239	251	B-Pathological_formation
multiforme	252	262	I-Pathological_formation
.	262	263	O

Tumour	264	270	B-Pathological_formation
angiogenesis	271	283	O
involves	284	292	O
multiple	293	301	O
cellular	302	310	O
processes	311	320	O
including	321	330	O
endothelial	331	342	B-Cell
cell	343	347	I-Cell
proliferation	348	361	O
,	361	362	O
migration	363	372	O
,	372	373	O
reorganisation	374	388	O
of	389	391	O
extracellular	392	405	B-Cellular_component
matrix	406	412	I-Cellular_component
and	413	416	O
tube	417	421	B-Tissue
formation	422	431	O
.	431	432	O

These	433	438	O
processes	439	448	O
are	449	452	O
regulated	453	462	O
by	463	465	O
numerous	466	474	O
pro	475	478	O
-	478	479	O
angiogenic	479	489	O
and	490	493	O
anti	494	498	O
-	498	499	O
angiogenic	499	509	O
growth	510	516	O
factors	517	524	O
.	524	525	O

Angiogenesis	526	538	O
inhibitors	539	549	O
have	550	554	O
been	555	559	O
developed	560	569	O
to	570	572	O
interrupt	573	582	O
the	583	586	O
angiogenic	587	597	O
process	598	605	O
at	606	608	O
the	609	612	O
growth	613	619	O
factor	620	626	O
,	626	627	O
receptor	628	636	O
tyrosine	637	645	O
kinase	646	652	O
and	653	656	O
intracellular	657	670	O
kinase	671	677	O
levels	678	684	O
.	684	685	O

Other	686	691	O
anti	692	696	O
-	696	697	O
angiogenic	697	707	O
therapies	708	717	O
alter	718	723	O
the	724	727	O
immune	728	734	O
response	735	743	O
and	744	747	O
endogeneous	748	759	O
angiogenesis	760	772	O
inhibitor	773	782	O
levels	783	789	O
.	789	790	O

Most	791	795	O
anti	796	800	O
-	800	801	O
angiogenic	801	811	O
therapies	812	821	O
for	822	825	O
malignant	826	835	O
gliomas	836	843	B-Pathological_formation
are	844	847	O
in	848	850	O
Phase	851	856	O
I	857	858	O
/	858	859	O
II	859	861	O
trials	862	868	O
and	869	872	O
only	873	877	O
modest	878	884	O
efficacies	885	895	O
are	896	899	O
reported	900	908	O
for	909	912	O
monotherapies	913	926	O
.	926	927	O

The	928	931	O
greatest	932	940	O
potential	941	950	O
for	951	954	O
angiogenesis	955	967	O
inhibitors	968	978	O
may	979	982	O
lie	983	986	O
in	987	989	O
their	990	995	O
ability	996	1003	O
to	1004	1006	O
combine	1007	1014	O
safely	1015	1021	O
with	1022	1026	O
chemotherapy	1027	1039	O
and	1040	1043	O
radiotherapy	1044	1056	O
.	1056	1057	O

